Member Info for HelloSanDiego

Geovanni - " I expect a big reveal on Thursday"

Why? If they have any news they're required to RNS it immediately.

RorkesDrift - Which interview is that?

I know a bit about AI and I'm not really seeing how much value there is to DVRG in that data. The bigger issue, in my opinion, would be in China allowing a non-Chinese plc unrestricted access to its environmental data. I'm interested to know what's actually been said about the hold-up.

That's not much of a delay then. Hopefully we'll get some good news soon. Thanks again.

Thanks. I see from the 28th April RNS that the JV was expected to be operational by 1 September 2021. Has there been any update in the past month about what's happening with it?

Have there been any details on what the China Resources JV could be worth to DVRG in terms of profit? And has that been confirmed or is it just hints and rumour?

I agree, a fundraise was never in doubt. The uncertainty is in what happens in the meantime and where it puts the share price when it happens.

That's the first solid confirmation I've seen that SAF is being widely adopted. It would've been better still if it were VLS. But regardless, it's good news.

It also goes some way to demonstrating why VLS could achieve, in the next 12 months, what they've been unable to in the past 12 years.

That's a tricky one: do I trust the respected doctor who's dedicated his life to medicine, or the commenter on a public forum who has a clear conflict of interest?

Simon McQueen Mason, a biologist from the University of York, is investigating ways of making gas and liquid fuel from biomass, by getting micro-organisms and bacteria to munch their way through woody material, and collecting the resulting gas and liquid produced as the bugs digest the biomass.

“Biofuel is probably the only way we can decarbonize the aviation industry in the next hundred years or so”, he says.

https://physicsworld.com/a/biomass-energy-green-or-dirty/

No, Richard Marsden used the word "treatments". I transcribe the interviews for my notes so I know that's correct.

April 30th 2021, Numis interview with Paul Cuddon: "On the drug product manufacturing we've got an aim to be able to produce 100k treatments per month..."

That's what led to the discussion on here as to whether that meant doses or courses. I don't think it was resolved.

Although the production schedule has slipped a bit from December 2020, the company still had enough cash to produce over a million treatments (although it was unclear whether that meant doses or courses).

I don't think there's any chance of a fundraise at anywhere near this price imo.

I've tried explaining it repeatedly, and in different ways. The usual response is "Gerry said just wait a bit longer".

They've made their minds up. GLA.

Newuncle,

I saw that RNS but unfortunately the sample is too small to draw a conclusive result, especially without additional data to clarify how they arrived at those figures.

That's normal, and it's why small trials are always followed by larger ones. But the real cause for concern is the lack of details. At the very least, the questions I posted at 10:07 should be answered. As I said before, there isn't any good reason not to give investors that information.

Newuncle,

here's Synairgen's but the same procedure is followed in all trials. You'll find hundreds on that site. It's standard practice to post the study method and participant numbers in advance of starting the trial, along with an estimated end date. There will also be updates along the way detailing when recruitment actually begins and is completed.

It's the only way investors can have any confidence that progress is being made and there's no good reason not to provide detailed updates.

https://clinicaltrials.gov/ct2/show/NCT04732949

I know it's not a popular opinion on here, but we really should be pressing for answers on the breath test, considering the notable total lack of transparency there.

I've invested in a few drug development companies that are progressing well. So I've spent a lot of time looking into clinical trials and these questions would normally be answered upfront.

How many volunteers have already been tested?
How many will be tested in total?
When is testing expected to be completed?

Rumours of the Microtox BT took us up to 70p *just on speculation alone*. So it really should be the focus.

ForrestGump - "GB says 'likely' to be 2022. He didn't use the words 'will be delayed to 2022' "

I think you're being generous there. It's entirely possible he threw in "likely" because it could end up being 2023 or later, or just to give the clique something to cling to.

Gerard clearly values posters' opinions on here Chesh, including yours.

So if you were less inclined to buy every excuse and more inclined to demand some explanations, the company might eventually reach one of its goals. I don't know about you but I'm not here for the fun of it.

Yesterday I posted on here asking for confirmation that Gerard said in the presentation that the breath test had been delayed until 2022. Two people answered.

Chesh said it hadn't.

Muggins said it had and posted a link. Here it is - https://youtu.be/lQOpoEzAZpc?t=1353

So he's got more credibility on here than anyone in my view. The conversation took place at around 15:50 yesterday for anyone who wants to verify it for themselves.

I don't think the general public will buy the STC concept as easily as some of the shareholders on here have.

It's £58m today, based on the current share price of 27p.

That's around 40% of where we were this time last year.